Counterpoint Mutual Funds’s Jazz Pharmaceuticals JAZZ Stock Holding History

Counterpoint Mutual Funds’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$724K	Hold	3,005	–	–	0.07%	115
2026 Q1	$568K	Buy	3,005 +42	+1%	+$7.34K	0.09%	121
2025 Q4	$504K	Buy	+2,963	New	+$454K	0.04%	130

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Counterpoint Mutual Funds's JAZZ Position: Q2 2026 in Review

Counterpoint Mutual Funds held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 3,005 shares worth $724K. The position accounts for 0.07% of the portfolio, ranked #115.

Counterpoint Mutual Funds first reported a position in JAZZ in Q4 2025 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Counterpoint Mutual Funds held 3,005 shares of Jazz Pharmaceuticals worth $724K as of Q2 2026.
Counterpoint Mutual Funds left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up 0.07% of Counterpoint Mutual Funds's portfolio in Q2 2026, its #115 holding.
Counterpoint Mutual Funds first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
89 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Counterpoint Mutual Funds's 13F filing for Q2 2026, filed 20 Jul 2026.